- Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update
- Vaxcyte to Present at the 23rd Annual Needham Virtual Healthcare Conference
- Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants
- Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Vaxcyte to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
- Vaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
- Vaxcyte to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference
- Vaxcyte Announces Pricing of $750 Million Public Offering
- Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
- Vaxcyte Completes Enrollment of Phase 1/2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease (IPD) in Adults Aged 50 and Older
More ▼
Key statistics
On Wednesday, Vaxcyte Inc (PCVX:NSQ) closed at 71.36, -13.02% below its 52-week high of 82.04, set on Feb 28, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 73.84 |
---|---|
High | 74.00 |
Low | 71.26 |
Bid | 56.50 |
Offer | 81.78 |
Previous close | 73.65 |
Average volume | 660.69k |
---|---|
Shares outstanding | 108.80m |
Free float | 106.21m |
P/E (TTM) | -- |
Market cap | 7.76bn USD |
EPS (TTM) | -4.22 USD |
Data delayed at least 15 minutes, as of May 22 2024 21:00 BST.
More ▼